FORM APPROVED

HEALTH CARE FINANCING ADMINISTRATION		OMB NO. 0938-0193
TRANSMITTAL AND NOTICE OF APPROVAL OF	1. TRANSMITTAL NUMBER:	2. STATE
STATE PLAN MATERIAL		
	2004-004	ARKANSAS
EOD. HEALTH CADE EINANCING ADMINISTRATION	3. PROGRAM IDENTIFICATION: T	ITLE XIX OF THE
FOR: HEALTH CARE FINANCING ADMINISTRATION	SOCIAL SECURITY ACT (MEDIC	CAID)
TO: REGIONAL ADMINISTRATOR	4. PROPOSED EFFECTIVE DATE	
HEALTH CARE FINANCING ADMINISTRATION		
DEPARTMENT OF HEALTH AND HUMAN SERVICES	October 15, 2004	
5. TYPE OF PLAN MATERIAL (Check One):		
☐ NEW STATE PLAN ☐ AMENDMENT TO BE	CONSIDERED AS NEW PLAN	igtimes AMENDMENT
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AME	ENDMENT (Separate Transmittal for each	ch amendment)
6. FEDERAL STATUTE/REGULATION CITATION:	7. FEDERAL BUDGET IMPACT:	
42 CFR 447, Subpart I	a. FFY 2005 \$	7,901,562
, 1		338,190,885
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:	9. PAGE NUMBER OF THE SUPER	
	OR ATTACHMENT (If Applicable	
when not 2 1 A B		·)·
Attachment 3.1-A, Page Saaa Attachment 3.1-A, Page 5aa	None, New Page Same, Approved 09/22/92, TN 91-35	
Attachment 3.1-B, Page 4h	Same, Approved 09/22/92, TN 91-35	
	Same, Approved 12/4/92)	TN1 91-59
Attachment 3.1-B, Page 4i	Sauce, Approved 1974 (2)	1,0,0,
10. SUBJECT OF AMENDMENT:		
Evidence-Based Preferred Drug List		
11. GOVERNOR'S REVIEW (Check One):		
☐ GOVERNOR'S OFFICE REPORTED NO COMMENT	OTHER, AS SPE	CIEIED:
COMMENTS OF GOVERNOR'S OFFICE ENCLOSED	_ Offick, No Si E	CHIED.
NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL		1
	$M_{c}$	1016 11
12. SIGNATURE OF STAIL AGENCY OFFICIAL:	16. RETURN TO:	fecture; 10/05/0
12. SIGNATURE OF STATE AGENCY OFFICIAL:	16. RETURN TO:	1: 11/23/04
$\frac{1}{2}$	Division of the second	growing " " "
13. TYPED NAME.	Division of Medical Services	tool 10/05/0
Mike R. Jeffus		persone, i , i , i ,
14. TITLE:	Little Rock, AR 72203-1437	
Director, Division of Medical Services		
15. DATE SUBMITTED:	Attention: Carolyn Patrick	
August 26, 2004		
FOR REGIONAL O	FFICE USE ONLY	
17 DATE DECEIVED:	18. DATE APPROVED:	
17. DATE ABCLIVED. 31 AUGUST 2004	23 NOVEMBER 2004	
PLAN APPROVED - O	The second of th	
19. EFFECTIVE DATE OF APPROVED MATERIAL:	20. SIGNATURE OF REGIONAL O	PETOLAT
15 OCTOBER 2004	20.500/4/08/09/09/09/09	
17. 36. 3997 (c. 1)	00 (DIDT D	
21. TYPED NAME:	22. TITLE: ASSOCIATE REGIONA	
ANDREW A. FREDRICKSON	DLV OF METDCAMO	CHILDREN'S HEALTH
23. REMARKS:		최고 프로토스 보다 있다.
	consider of additional	Dance soc states
& Pen + Ink change including a	prove or accorning	Tyes per sieses
* Pen + Ink Change including ay c-mail dated 11/16/04.	(프로그램 조건 다시 그리 바라가 있는 해당되었다.	
c-ruit auteu 1/10/04.		
	되겠다. 항송하는 병이 지나는 그 모든 것이다.	

## STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT MEDICAL ASSISTANCE PROGRAM STATE <u>ARKANSAS</u>

ATTACHMENT 3.1-B Page 4i

AMOUNT, DURATION AND SCOPE OF SERVICES PROVIDED

Revised:

October 15, 2004

**MEDICALLY NEEDY** 

- 12. Prescribed drugs, dentures and prosthetic devices; and eyeglasses prescribed by a physician skilled in diseases of the eye or by an optometrist (Continued)
  - a. Prescribed Drugs (continued)

Prior authorization will be established for certain drug classes, particular drugs or medically accepted indication for uses and doses.

The state will appoint a Pharmaceutical and Therapeutic Committee or utilize the drug utilization review committee in accordance with Federal law.

When a pharmacist receives a prescription for a brand or trade name drug, and dispenses an innovator multisource drug that is subject to the Federal Upper Limits (FULs), the innovator multisource drug must be priced at or below the FUL or the prescription hand annotated by the prescriber "Brand Medically Necessary". Only innovator multisource drugs that are subject to the Federal Upper Limit at 42 CFR 447.332(a) and dispensed on or after July 1, 1991, are subject to the provisions of Section 1903(i)(10)(B) of the Social Security Act.

For drugs listed on the Arkansas Medicaid Generic Upper Limit List, the upper limit price will not apply if the prescribing physician certifies in writing that a brand name drug is medically necessary.

The Arkansas Medicaid Generic Upper Limit List is comprised of State generic upper limits on specific multisource drug products and **CMS** identified generic upper limits on multisource drug products.

### b. Dentures

Refer to Attachment 3.1-B Item 4.b(7) for coverage of dentures for Child Health Services (EPSDT) recipients.

A LANGE OF THE PARTY OF THE PAR	
STATE Arkansas	
DATE REC'D 8-31-04	
DATE APPV'D 11-23-04	Α
DATE EFF 10-15-04	
HCFA 179	l

# STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT MEDICAL ASSISTANCE PROGRAM STATE <u>ARKANSAS</u>

ATTACHMENT 3.1-B Page 4h

AMOUNT, DURATION AND SCOPE OF SERVICES PROVIDED

Revised:

October 15, 2004

**MEDICALLY NEEDY** 

- 12. Prescribed drugs, dentures and prosthetic devices; and eyeglasses prescribed by a physician skilled in diseases of the eye or by an optometrist (Continued)
  - a. Prescribed Drugs (continued)
    - (4) The state is in compliance with section 1927 of the Social Security Act. The state will cover drugs of Federal rebate participating manufacturers. The state is in compliance with reporting requirements for utilization and restrictions to coverage. Pharmaceutical manufacturers can audit utilization data.

The state will be negotiating supplemental rebates in the Medicaid program in addition to the Federal rebates provided for in Title XIX. Rebate agreements between the state and pharmaceutical manufacturer(s) will be separate from the Federal rebates.

A rebate agreement between the state and a participating drug manufacturer for drugs provided to the Medicaid program, submitted to CMS on November 16, 2004, and entitled, State of Arkansas Supplemental Rebate Agreement, has been authorized by CMS. Any additional versions of rebate agreements negotiated between the state and manufacturer(s) after November 16, 2004, will be submitted to CMS for authorization.

Supplemental rebates received by the State in excess of those required under the National Drug Rebate Agreement will be shared with the Federal government on the same percentage basis as applied under the national rebate agreement.

All drugs covered by the program, irrespective of a supplemental rebate agreement, will comply with the provisions of the national drug rebate agreement.

The supplemental rebate program does not establish a drug formulary within the meaning of 1927(d)(4) of the Social Security Act.

The unit rebate amount is confidential and cannot be disclosed for purposes other than rebate invoicing and verification, in accordance with Section 1927(b)(3)(D) of the Social Security Act.

(5) Pursuant to 42 U.S.C. Section 1396r-8 the state is establishing a preferred drug list with prior authorization for drugs not included on the preferred drug list. Prior authorization will be provided within a 24-hour turn-around from receipt of request and a 72-hour supply of drugs in emergency situations.

	· · · · · · · · · · · · · · · · · · ·	
	STATE Arkansas DATE REC'D 3-31-04	Α
١	DATE APPV'D 11-23-04	
	DATE EFF 10-15-04	1
	HCFA 179 04-04	1

# STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT MEDICAL ASSISTANCE PROGRAM STATE ARKANSAS

ATTACHMENT 3.1-A Page 5aa

AMOUNT, DURATION AND SCOPE OF SERVICES PROVIDED

Revised:

October 15, 2004

#### CATEGORICALLY NEEDY

- 12. Prescribed drugs, dentures and prosthetic devices; and eyeglasses prescribed by a physician skilled in diseases of the eye or by an optometrist (Continued)
  - a. Prescribed Drugs (continued)
    - (4) The state is in compliance with section 1927 of the Social Security Act. The statewill cover drugs of Federal rebate participating manufacturers. The state is in compliance with reporting requirements for utilization and restrictions to coverage. Pharmaceutical manufacturers can audit utilization data.

The state will be negotiating supplemental rebates in the Medicaid program in addition to the Federal rebates provided for in Title XIX. Rebate agreements between the state and pharmaceutical manufacturer(s) will be separate from the Federal rebates.

A rebate agreement between the state and a participating drug manufacturer for drugs provided to the Medicaid program, submitted to CMS on November 16, 2004, and entitled, State of Arkansas Supplemental Rebate Agreement, has been authorized by CMS. Any additional versions of rebate agreements negotiated between the state and manufacturer(s) after November 16, 2004, will be submitted to CMS for authorization.

Supplemental rebates received by the State in excess of those required under the National Drug Rebate Agreement will be shared with the Federal government on the same percentage basis as applied under the national rebate agreement.

All drugs covered by the program, irrespective of a supplemental rebate agreement, will comply with the provisions of the national drug rebate agreement.

The supplemental rebate program does not establish a drug formulary within the meaning of 1927(d)(4) of the Social Security Act.

The unit rebate amount is confidential and cannot be disclosed for purposes other than rebate invoicing and verification, in accordance with Section 1927(b)(3)(D) of the Social Security Act.

(5) Pursuant to 42 U.S.C. Section 1396r-8 the state is establishing a preferred drug list with prior authorization for drugs not included on the preferred drug list. Prior authorization will be provided within a 24-hour turn-around from receipt of request and a 72-hour supply of drugs in emergency situations.

STATE Arkansas

DATE REC'D 8-31-04

DATE APPVID 11-23-04

DATE EFF 10-15-04

HCFA 179 04-04

2000 7 9 9 91-35

## STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT MEDICAL ASSISTANCE PROGRAM STATE <u>ARKANSAS</u>

ATTACHMENT 3.1-A Page 5aaa

AMOUNT, DURATION AND SCOPE OF SERVICES PROVIDED

#### **CATEGORICALLY NEEDY**

October 15, 2004

- 12. Prescribed drugs, dentures and prosthetic devices; and eyeglasses prescribed by a physician skilled in diseases of the eye or by an optometrist (Continued)
  - a. Prescribed Drugs (continued)

Prior authorization will be established for certain drug classes, particular drugs or medically accepted indication for uses and doses.

The state will appoint a Pharmaceutical and Therapeutic Committee or utilize the drug utilization review committee in accordance with Federal law.

When a pharmacist receives a prescription for a brand or trade name drug, and dispenses an innovator multisource drug that is subject to the Federal Upper Limits (FULs), the innovator multisource drug must be priced at or below the FUL or the prescription hand annotated by the prescriber "Brand Medically Necessary". Only innovator multisource drugs that are subject to the Federal Upper Limit at 42 CFR 447.332(a) and dispensed on or after July 1, 1991, are subject to the provisions of Section 1903(i)(10)(B) of the Social Security Act.

For drugs listed on the Arkansas Medicaid Generic Upper Limit List, the upper limit price will not apply if the prescribing physician certifies in writing that a brand name drug is medically necessary.

The Arkansas Medicaid Generic Upper Limit List is comprised of State generic upper limits on specific multisource drug products and CMS identified generic upper limits on multisource drug products.

STATE ACKANSAS

DATE REC'E 8-31-04

DATE APPYO 11-23-04

DATE EFF 10:15-04

HCFA 179 04-04